Fig. 7. Inhibition of EL activity in EC-specific Angptl4 KO mice normalizes EC metabolism and angiogenesis.

a Scheme showing the experimental strategy. b–f Tumor analysis of WT Ctrl (n = 5), WT XEN445 treated (n = 6), Angptl4^iΔEC Ctrl (n = 5) mice and Angptl4^iΔEC XEN445 treated (n = 6) with s.c. injection of LLCs in the dorsal flank. b Tumor volume. c Left, representative micrographs of CD31 (red) and DAPI (blue) immunostaining. Right, Quantification of CD31⁺ vessel-like structures (n = 5 quantified) d Left panel, representative micrographs of immunofluorescence staining of CD31 (red), 2NBDG (green) and DAPI (blue). Right panel, quantification of 2NBDG positive CD31 positive vessel-like structures. e Left, Representative micrographs showing immunostaining of CD31 (red) and fluorescent FA (BODIPY-FL-C16) (green). f Left, representative micrographs of CD31 (red) and CD36 (green) immunostaining. Right panels (d–f) are quantification of at least 4 different images from each mouse. (n = 3 quantified per genotype out of 5 or 6 randomly selected, except for e (n = 4 quantified). Scale bars, 100μm (c and d), 125 μm (e and f). Data are represented as means ± SEM. Two-way ANOVA with Tukey’s multiple comparisons test in (b–d). One-way ANOVA with Tukey’s multiple comparisons test in (e) and (f). Exact p values are shown for each comparison. Source data are provided as a Source data file.